Posted On: 06/18/2014 12:09:18 AM
Post# of 30066
Any ideas when these results are due in??if good aren't we on the same path with MANF? This would move the PPS......
MedGenesis Therapeutix Inc. is in late Phase II trials involving its glial cell line derived neurotropic factor (GDNF), and is discussing terms sheets with big pharma, according to Erich Mohr, chairman and CEO. “We’re developing what we hope will be the definitive treatment.” GDNF is based on the Amgen compound, which had delivery problems. “At the time, technology was not mature enough to allow the compound to effectively cross the blood-brain barrier. We solved that.” MedGenesis’s approach uses 3D neuroimaging and robotic surgery for unprecedented delivery accuracy. Neurosurgeons are familiar with deep brain stimulations and so are receptive to this approach, he says. The company also is working closely – through biweekly phone calls – with the Michael J. Fox Foundation, which also helped convene this panel. 1/20/2014
MedGenesis Therapeutix Inc. is in late Phase II trials involving its glial cell line derived neurotropic factor (GDNF), and is discussing terms sheets with big pharma, according to Erich Mohr, chairman and CEO. “We’re developing what we hope will be the definitive treatment.” GDNF is based on the Amgen compound, which had delivery problems. “At the time, technology was not mature enough to allow the compound to effectively cross the blood-brain barrier. We solved that.” MedGenesis’s approach uses 3D neuroimaging and robotic surgery for unprecedented delivery accuracy. Neurosurgeons are familiar with deep brain stimulations and so are receptive to this approach, he says. The company also is working closely – through biweekly phone calls – with the Michael J. Fox Foundation, which also helped convene this panel. 1/20/2014
(0)
(0)
